±³½Ç¼Ò°³

    • home
    • ±³½Ç¼Ò°³
    • ±âÃÊÀÇÇÐ

±âÃÊÀÇÇÐ

  • ÀüÀÓ±³¼ö(ÀÇ°ú´ëÇÐ)
  • ±èÅÂÁø
  • ȨÆäÀÌÁö ¹Ù·Î°¡±â http://biomed.skku.edu/immunopathol
  • Àü°øºÐ¾ß £ü ¸é¿ªÇÐ, ¸é¿ªº´¸®
  • ¿¬¶ôó     £ü (ÀüÈ­) 031-299-6161 / (fax) 031-290-7909
  • À̸ÞÀÏ     £ü tjkim@skku.edu

ÁÖ¿ä°æ·Â

  • 1988 ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ Çлç
    1993 ¼­¿ï´ëÇб³º´¿ø º´¸®°ú Àü¹®ÀÇ
    1994 ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÇйڻç
    1997 Harvard Medical School & MGH cancer center, research fellow
    1998-ÇöÀç ¼º±Õ°ü´ë ÀÇ°ú´ëÇÐ Á¶±³¼ö, ºÎ±³¼ö, ±³¼ö

ÁÖ¿ä°ü½É¿¬±¸

  • 1) B1¼¼Æ÷ÀÇ ¾Æ±º Ư¼º
    B¼¼Æ÷´Â ±Ã±ØÀûÀ¸·Î Ç×ü¸¦ ºÐºñÇÏ´Â ¼¼Æ÷ÀÌÁö¸¸ ¿ÏÀüÇÑ effector ¼¼Æ÷ÀÎ Ç×üºÐºñ¼¼Æ÷ (ÇüÁú¼¼Æ÷, plasma cell)·Î ºÐÈ­µÇ±â µÇ±â Àü±îÁö ¸Å¿ì º¹ÀâÇÑ ºÐÈ­ °úÁ¤À» °ÅÄ£´Ù. B¼¼Æ÷´Â ´Ü¼øÇÑ ÇÑ °¡Áö Á¾·ùÀÇ ¼¼Æ÷°¡ ¾Æ´Ï¶ó ±â´ÉÀû Ư¼ºÀÌ ´Ù¸¥ ¾Æ±ºµé·Î ³ª´©¾îÁö´Âµ¥ ÀÌ ¾Æ±ºµéÀº ¸é¿ª°è¿¡¼­ ¼­·Î »óº¸ÀûÀÎ ´Ù¸¥ ±â´ÉÀ» °¡Áø´Ù. Å©°Ô º¼ ¶§ B¼¼Æ÷´Â ÁÖ¾îÁø Ç׿ø¿¡ ´ëÇØ °íģȭµµ Ç×ü¸¦ »ý»êÇÒ ¼ö ÀÖ´Â B2¼¼Æ÷¿Í ¹Ì¸® ºÐÈ­ÀûÀ¸·Î ¿¹Á¤µÇ¾î ÀÖÀ¸¸ç ÀÚ¿¬ Ç×ü¸¦ ºÐºñÇÏ´Â B1¼¼Æ÷·Î ³ª´©¾î º¼ ¼ö ÀÖ´Ù. ±× Áß B1¼¼Æ÷°¡ ¿ì¸®ÀÇ ÁÖ¿ä ¿¬±¸ ÁÖÁ¦·Î ¿ì¸®´Â ´ÙÀ½°ú °°Àº Áú¹®À» Á¦½ÃÇÏ°í ´äÀ» ã°íÀÚ ÇÏ°í ÀÖ´Ù.

    (1) B1¼¼Æ÷´Â ¾î¶»°Ô ¼±ÅõǴ°¡. ¹ÚÅ׸®¾Æ µî¿¡ ¹ÝÀÀÇÏ´Â Ç×ü°¡ B1¼¼Æ÷·Î¼­ ¼±ÅõǴµ¥ °³Ã¼ ¹ß»ý »ó¿¡¼­ ž±â ÀÌÀü¿¡´Â ÀÌ·¯ÇÑ Ç׿øÀ» ¸¸³¯ ¼ö ¾øÀ½¿¡µµ ºÒ±¸ÇÏ°í ¾î¶»°Ô ¹ß´ÞÇÒ ¼ö Àִ°¡?
    (2) B1¼¼Æ÷ÀÇ ¸é¿ª¹ÝÀÀ¿¡ ÀÖ¾î toll-like receptor¿Í °°Àº ÀÚ¿¬¸é¿ª¼ö¿ëü¿Í B¼¼Æ÷ ¼ö¿ëü °£ÀÇ ¾î¶°ÇÑ »óÈ£ÀÛ¿ëÀÌ Àִ°¡? B2¼¼Æ÷¿Í ´Þ¸® ÀÚ¿¬¸é¿ª¼ö¿ëüÀÇ ¸é¿ª¹ÝÀÀ¿¡¼­ÀÇ ¿ªÇÒÀÌ Å«µ¥ ÀÌ ½ÅÈ£´Â B¼¼Æ÷ ¼ö¿ëü¿Í »óÈ£ÀÛ¿ëÇÏ¿© ¸é¿ª¹ÝÀÀÀ» À¯µµÇÏ´Â °ÍÀ¸·Î º¸À̴µ¥ ±× »óÈ£ÀÛ¿ë ¹æ½ÄÀº ¾î¶°ÇÑ °ÍÀΰ¡?
    (3) B1¼¼Æ÷ÀÇ ´Ù¾ç¼ºÀº ±³°ú¼­ÀûÀ¸·Î B2¼¼Æ÷º¸´Ù ¶³¾îÁø´Ù°í Çϴµ¥ ½ÇÁ¦·Î ´Ù¾ç¼ºÀÇ Â÷ÀÌ°¡ È®ÀεǴ°¡? º» ¿¬±¸½Ç¿¡´Â B¼¼Æ÷¼ö¿ëüÀÇ ´Ù¾ç¼º°ú B cell receptor repertoireÀÇ Æ¯Â¡À» ü°èÀûÀ¸·Î ºÐ¼®ÇÏ°í ÀÖÀ¸¸ç º¸´Ù ÀÚ¿¬ÀûÀÎ ¸é¿ª¹ÝÀÀ°úÁ¤À» ¸ðµ¨¸µÇÏ°íÀÚ ÇÏ°í ÀÖ´Ù.

    ¶Ç ÀÌ·¯ÇÑ ¹°À½¿¡ ´äÇϱâ À§ÇÑ ¿¬±¸·Î ¸¶¿ì½ºÀÇ º¹°­ ³» peritoneal B cellÀ» ºÐ¸®ÇÏ°í ÀÚ¿¬¸é¿ª ¹× B¼¼Æ÷ ¼ö¿ëü ÀÚ±ØÀ» ÅëÇÑ ½ÅÈ£Àü´Þ°ú ¼¼Æ÷ÀÇ À̵¿ Ư¼ºÀ» º¯È­¸¦ º¸°í ÀÖ´Ù. ƯÈ÷ ÇüÁú¼¼Æ÷·ÎÀÇ ºÐÈ­¿Í Ç×ü ºÐºñ ¹× chemokine receptorÀÇ Ç¥Çö°ú chemokine¿¡ ´ëÇÑ À̵¿ ¹ÝÀÀ¼ºÀ» ¿¬±¸ÇÏ°í ÀÖ´Ù.

    2) CD99 À¯ÀüÀÚÀÇ ±â´É°ú ¼¼Æ÷ À̵¿
    CD99 ´Ü¹éÀº ¸²ÇÁ±¸¿Í Ç÷°ü³»ÇǼ¼Æ÷ µî¿¡ Ç¥ÇöµÇ´Â ¼¼Æ÷Ç¥¸é´Ü¹éÀ¸·Î ¼¼Æ÷°£ »óÈ£ÀÛ¿ëÀ» Á¶ÀýÇϸç ÀÌ »óÈ£ÀÛ¿ëÀÌ ´ë½Ä¼¼Æ÷°¡ Ç÷°ü ³»¿¡¼­ º°°ü ¹ÛÀ¸·Î À̵¿Çϴµ¥ ÇÊ¿äÇÏ´Ù°í º¸°íµÇ¾ú´Ù. ¿ì¸®´Â CD99ÀÇ ½ÅÈ£Àü´Þ °æ·Î¸¦ º¸¿´À¸¸ç T¼¼Æ÷ ¼ö¿ëü¿¡ ´ëÇÑ costimulatory molecule·Î ¿ªÇÒÇÔÀ» º¸¿´´Ù. ¶ÇÇÑ CD99 Àڱؿ¡ ÀÇÇÏ¿© À¯µµµÇ´Â ¼¼Æ÷°ñ°ÝÀ» º¯È­¸¦ º¸°íÇÏ¿´´Ù. ÇöÀçÀÇ ¿¬±¸´Â CD99ÀÇ ¸¶¿ì½º ÇüÀÌ º¸°íµÊ¿¡ µû¶ó ÀÌ°ÍÀÇ Ç¥Çö Á¶Àý ¾ç»óÀ» ºÐ¼®ÇÏ¿´À¸¸ç »ç¶÷°ú ´Þ¸® ¸¶¿ì½º¿¡¼­´Â ÀÇ¿Ü·Î B1¼¼Æ÷¿¡¼­ CD99ÀÇ Ç¥ÇöÀÌ ³ôÀ½À» °üÂûÇÏ¿´´Ù. ¿ì¸®´Â CD99°¡ B1¼¼Æ÷ÀÇ À̵¿ ¹× Ç×ü ºÐºñ¿¡ Áß¿äÇÑ Á¶ÀýÀÎÀÚ·Î º¸°í ¸¶¿ì½º CD99ÀÇ ½ÅÈ£Àü´Þ ¹× B1¼¼Æ÷ ±â´É Á¶ÀýÀ» ¿¬±¸ÇÏ°í ÀÖ´Ù.

    3) Syk Ƽ·Î½Å Å°³ªÁ¦ÀÇ »õ·Î¿î ±âÁú°ú ¼¼Æ÷ À̵¿
    Syk Å°³ªÁ¦´Â B¼¼Æ÷¿¡¼­ óÀ½ ±× ±â´ÉÀÌ ¾Ë·ÁÁ³À¸¸ç B¼¼Æ÷ ¼ö¿ëü¸¦ ÅëÇÑ ½ÅÈ£¿¡ ÇʼöÀûÀÎ Å°³ªÁ¦ÀÌ´Ù. ÃÖ±Ù¿¡´Â ¾Ï¼¼Æ÷¿¡¼­ Ç¥ÇöÀÌ ¾Ë·ÁÁ³À¸¸ç SykÀÇ Ç¥ÇöÀº ¾ÏÀÇ ÀüÀÌ¿Í Ä§¹ü¼º¿¡ ´ëÇØ ¿ªºñ·Ê °ü°è¸¦ °¡Áö´Â ¸Å¿ì Áß¿äÇÑ ¾Ï¾ïÁ¦ À¯ÀüÀÚ·Î »ý°¢µÇ°í ÀÖ´Ù. º» ¿¬±¸½ÇÀº ÀÌ Å°³ªÁ¦ÀÇ ±âÁúÀ» systemic ÇÏ°Ô Ã£°íÀÚ ÇÏ¿´À¸¸ç ÇöÀç ¼ö½ÊÁ¾ÀÇ Èĺ¸ ±âÁú À¯ÀüÀÚ¸¦ °¡Áö°í SykÀÇ B¼¼Æ÷¿Í ¾Ï¼¼Æ÷ÀÇ À̵¿¿¡ °ü°èÇÏ´Â ±âÀüÀ» ¿¬±¸ÇÏ°í ÀÖ´Ù.

´ëÇ¥¿¬±¸¾÷Àû

  • 1. Lee, S., Ko, Y., Lee, H.W., Oh, W.J., Homg, H.G., Ariyaratne, D., Im, S.J.*, and Kim, T.J.* Two Distinct Subpopulations of Marginal Zone B Cells Exhibit Differential Antibody-Producing Ca-pacity and Radioresistance. Cell Mol Immunol. in press (2024).
    2. Lee, S., Chung, Y. S., Lee, K. W., Choi, M., Sonn, C. H., Oh, W. J., .. Kim, T.J.* Alteration of gammadelta T cell subsets in non-human primates transplanted with GGTA1 gene-deficient porcine blood vessels. Xenotransplantation.e12838 online.
    3. Lee, S., Yang, J. I., Lee, J. H., Lee, H. W., Kim, T. J.* Low-Level Expression of CD138 Marks Naturally Arising Anergic B Cells. Immune Netw. 22(6):e50 (2022).
    4. Lee, H. W., Park, C., Joung, J. G., Kang, M., Chung, Y. S., Oh, W. J., .. Kim, T.J.,* Seo,S.I.* Renal Cell Carcinoma-Infiltrating CD3(low) Vgamma9Vdelta1 T Cells Represent Potentially Novel Anti-Tumor Immune Players. Curr Issues Mol Biol. 43(1):226-239 (2021).
    5. Lee, S., Ko, Y., Kim, T. J.* Homeostasis and regulation of autoreactive B cells. Cell Mol Immunol. 17(6):561-569 (2020).
    6. Lee, H. W., Chung, Y. S., Kim, T. J.* Heterogeneity of Human gammadelta T Cells and Their Role in Cancer Immunity. Immune Netw. 20(1):e5 (2020).
    7. Liu, W.,* Tolar, P.,* Song, W.,* Kim, T. J.* Editorial: BCR Signaling and B Cell Activation. Front Immunol. 11:45 (2020).
    8. Lee, M., Park, C., Woo, J., Kim, J., Kho, I., Nam, D. H., .. Kong, D.S., Kim, T.J.* Preferential Infiltration of Unique Vgamma9Jgamma2-Vdelta2 T Cells Into Glioblastoma Multiforme. Front Immunol. 10:555 (2019).
    9. Zhao, X., Xie, H., Zhao, M., Ahsan, A., Li, X., Wang, F., .. Kim, T.J.,* Liu, W.* Fc receptor-like 1 intrinsically recruits c-Abl to enhance B cell activation and function. Sci Adv. 5(7):eaaw0315 (2019).
    10. Lee, J. G., Jang, J. Y., Fang, T., Xu, Y., Yan, J. J., Ryu, J. H., .. Kim, T.J.*, Yang, S.* Identification of Human B-1 Helper T Cells With a Th1-Like Memory Phenotype and High Integrin CD49d Expression. Front Immunol. 9:1617 (2018).
    11. Park, C., Kim, T. J.* Expansion and Sub-Classification of T Cell-Dependent Antibody Responses to Encompass the Role of Innate-Like T Cells in Antibody Responses. Immune Netw. 18(5):e34 (2018).